

Commissioning Policy

Hyalurons, Hyaluronic Acid or Viscosupplementation

Intervention Not Normally Funded (INNF)

Date adopted: 10.06.2025

Version: 1.3

Authorisation and document control

Name of policy:	Hyalurons, Hyaluronic Acid or Viscosupplementation
Job title of author:	Senior Programme Commissioning Manager
Name of sign off group:	Commissioning Policy Review Group

Equality and Engagement Impact Assessment	
Date Equality and Engagement Impact Assessment was completed:	30.05.2025

Consultation	
Name of group	Date considered
MSK CPG clinical lead	April 2025

Authorisation	
Name of group	Date approved
Commissioning Policy Review Group	10.06.2025
System Quality Committee	20.08.2015

Date of adoption	10.06.2025
Date of publication	June 2025
Review date	June 2028
To be reviewed by (job title)	Senior Programme Commissioning Manager

Version control				
Version number	Date	Summary of changes	Author/Editor	Approved by
1.0	October 2015	Policy created	IFR Manager	ECCP Group
1.1	March 2018	No changes. Review date updated	IFR Manager	ECCP Group
1.2	March 2022	No changes. Review date updated.	Programme Manager	ECCP Group
1.3	June 2025	Policy moved to new policy template. No changes to content	Senior Programme Manager	CPRG

1.0 Background

Hyaluronic acid is similar to a substance that occurs naturally in the joints. It works by acting like a lubricant and shock absorber in the joints and helps the joints to work properly. Evidence on the effectiveness of these injections is mixed, but there is sufficient evidence suggesting that treatment has limited gains for the National Institute for Health and Clinical Excellence to conclude that it should not be offered as a treatment for osteoarthritis (NICE NG226). It is therefore not normally available on the NHS.

2.0 Policy statement

Policy details
Hyalurons, Hyaluronic Acid or viscosupplementation as a treatment for osteoarthritis is not normally funded.

3.0 Patients who are not eligible for treatment under this policy

Patients who are not eligible for treatment under this policy may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy.

Individual cases will be reviewed at the ICB's Individual Funding Request Panel upon receipt of a completed application form from the patient's GP, Consultant or Clinician. Applications cannot be considered from patients personally.

4.0 Connected policies

None

5.0 References

NICE Guideline, NG226 [Recommendations | Osteoarthritis in over 16s: diagnosis and management | Guidance | NICE](#)